PRME Stock Risk & Deep Value Analysis
Prime Medicine Inc
Healthcare • Biotechnology
DVR Score
out of 10
What You Need to Know About PRME Stock
We analyzed Prime Medicine Inc using our deep value framework. Sign in to see our full verdict and DVR Score.
We ran PRME through our deep value framework — analyzing financial health, distress signals, competitive moat, and risk factors. Our risk assessment: Aggressive. Here's what we found.
PRME Risk Analysis & Red Flags
What Could Go Wrong
Prime Medicine is burning significant cash (previously -$167M TTM FCF). If clinical trials face delays or failures, or if funding markets tighten, the company may need substantial dilution to sustain operations, severely impacting shareholder value before any commercial success.
Risk Matrix
Overall
Aggressive
Financial
High
Market
Medium
Competitive
High
Execution
High
Regulatory
High
Red Flags
- ⚠
Persistent negative free cash flow with no clear path to profitability
- ⚠
Long development timelines inherent to gene editing therapies
- ⚠
Reliance on external funding which poses ongoing dilution risk
- ⚠
Lack of near-term revenue generation
Upcoming Risk Events
- 📅
Unfavorable clinical trial results or unexpected side effects
- 📅
Significant share dilution from future capital raises
- 📅
Increased competitive pressure from other gene editing modalities
When to Reconsider
- 🚪
Significant deceleration or complete halt of a lead clinical program
- 🚪
Cash runway falls below 12 months without clear financing plans
- 🚪
Share dilution event exceeding 20-30% of outstanding shares
Unlock PRME Risk Analysis & Red Flags
Create a free account to see the full analysis
What Does Prime Medicine Inc (PRME) Do?
Market Cap
$640.06M
Sector
Healthcare
Industry
Biotechnology
Employees
214
Prime Medicine, Inc., a biotechnology company, engages in delivering genetic therapies to address the spectrum of diseases by deploying gene editing technology in the United States. It offers Prime Editing technology comprising a programmable DNA binding domains, such as Cas domains, are typically modified such that they do not cause a double-stranded break in the DNA, as well as a RT domain that copies the edited DNA sequence directly into the target genomic site where the edit is made; and pegRNA which contains a search sequence, also known as a spacer, which provides a target genomic address for the Prime Editor. The company has a research collaboration with Cimeio Therapeutics to develop Prime Edited Shielded-Cell & Immunotherapy Pairs for genetic diseases, acute myeloid leukemia, and myelodysplastic syndrome. Prime Medicine, Inc. was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.
Visit Prime Medicine Inc WebsiteInvestment Thesis
Prime Medicine possesses a potentially revolutionary gene editing technology ('Prime Editing') that could offer superior precision and broader therapeutic applicability compared to existing methods. While early-stage and cash-intensive, successful clinical development and strategic partnerships could enable it to capture a significant share of the vast genetic disease market, driving substantial long-term value.
Is PRME Stock Undervalued?
Unlock the full AI analysis for PRME
Get the complete DVR score, risk analysis, and more
Unlock the full report
Create a free account to see the DVR score, risk flags, and AI analysis.
PRME Price Targets & Strategy
12-Month Target
$6.50
Bull Case
$10.00
Bear Case
$2.00
Valuation Basis
Target based on previously established analyst consensus price target ($7.38 median) discounted slightly due to ongoing cash burn and lack of new positive catalysts, reflecting early-stage biotech pipeline valuation.
Entry Strategy
Dollar-cost average at current levels (around $3.45) if conviction in technology is high, or await clearer clinical milestones. Technical support is limited given volatility.
Exit Strategy
Take profit at $8.00-$10.00 if significant clinical data or partnership news emerges. Set stop-loss at $2.50 if cash burn accelerates or major clinical setbacks occur.
Portfolio Allocation
2-4% for aggressive risk tolerance, given the early stage and high-risk profile.
Price Targets & Strategy
Upgrade to Premium for price targets and entry/exit strategies
Is PRME Financially Healthy?
Valuation
P/E Ratio
-6.49
Price/Sales
131.22
Profitability
Operating Margin
-4498.06%
Net Margin
-4342.44%
Return on Equity
-178.61%
Revenue Growth
55.28%
EPS
$-1.38
Balance Sheet
Current Ratio
4.84
Quick Ratio
4.76
Other
Beta (Volatility)
2.35
Does PRME Have a Competitive Moat?
Sign in to unlockMoat Rating
🛡️ Narrow
Moat Trend
Expanding
Moat Sources
2 Identified
The moat's durability hinges on continued clinical success, effective patent defense, and the ability to demonstrate clear superiority of Prime Editing over competing technologies without being easily replicated or surpassed.
Moat Erosion Risks
- •Emergence of superior or equally effective gene editing technologies from competitors
- •Challenges to its intellectual property or patent infringement lawsuits
- •Clinical failures that erode confidence in the technology platform
PRME Competitive Moat Analysis
Sign up to see competitive advantages
PRME Market Intelligence
Sentiment & Insider Activity
Social Sentiment
Neutral - The innovative technology generates interest, but the high-risk, early-stage nature dampens widespread bullishness.
Institutional Sentiment
Mixed - Analyst median price target increased previously, but recent calls were mixed, indicating a divided institutional view on near-term prospects vs. long-term potential.
Insider Activity (Form 4)
No recent specific insider activity reported in provided research as of 2026-05-01.
Options Flow
Normal options activity - No specific unusual options activity or significant directional bets reported in provided research.
Earnings Intelligence
Next Earnings
Estimated Q1 2026 (date unknown as of 2026-05-01)
Surprise Probability
Medium
Historical Earnings Pattern
Stock price reaction is highly sensitive to clinical trial news, cash burn figures, and financing announcements rather than traditional revenue/EPS beats, often leading to volatile swings.
Key Metrics to Watch
Competitive Position
Top Competitor
CRISPR Therapeutics (CRSP)
Market Share Trend
Gaining mind share and potential future market share as its Prime Editing technology gains validation, but currently has no commercial market share.
Valuation vs Peers
Trades at a discount on market cap and implied pipeline valuation to more advanced gene editing peers like CRSP, reflecting its earlier stage of clinical development and lack of late-stage assets.
Competitive Advantages
- •Proprietary Prime Editing technology offering enhanced precision and broader applicability than CRISPR
- •Robust intellectual property portfolio protecting its core technology
- •Potential for fewer off-target edits compared to other gene editing platforms
Market Intelligence
Get sentiment, earnings intel, and peer analysis with Premium
What Could Drive PRME Stock Higher?
Near-Term (0-6 months)
- •Estimated Q1 2026 earnings report (date unknown as of 2026-05-01)
- •Updates on ongoing preclinical or early-stage clinical programs
- •Potential new research collaborations or small-scale partnerships
Medium-Term (6-18 months)
- •Advancement of lead programs (e.g., PM359) into later-stage clinical trials
- •Successful Investigational New Drug (IND) application filings for new targets
- •Expanded manufacturing capabilities or technology platform enhancements
Long-Term (18+ months)
- •Positive pivotal clinical trial results for a lead candidate
- •Regulatory approval and commercialization of a Prime Editing therapy
- •Broad application of Prime Editing technology across multiple therapeutic areas
Catalysts & Growth Drivers
Upgrade to Premium to see catalysts
What's the Bull Case for PRME?
- ✓
Positive clinical data readouts (Phase 1/2 results)
- ✓
New or expanded collaborations with pharmaceutical partners
- ✓
Successful capital raises that extend cash runway without excessive dilution
Bull Case Analysis
See what could go right with Premium
Competing with PRME
See how Prime Medicine Inc compares to related companies
| Company | Market Cap | DVR Score | P/E | Revenue | Profit Margin | Rev Growth | |
|---|---|---|---|---|---|---|---|
Prime Medicine Inc PRME | $640.1M | 3.8 | -6.5 | $4.6M | -4342.4% | 55.3% | |
AbbVie Inc ABBV | $403.8B | 0.1 | 171.8 | — | — | — | Compare → |
Johnson & Johnson JNJ | — | 1.0 | — | — | — | — | Compare → |
Eli Lilly and Co LLY | $965.0B | 0.5 | 52.6 | — | — | — | Compare → |
Pfizer Inc PFE | $150.6B | 0.2 | 19.4 | $62.6B | 12.4% | -1.6% | Compare → |
UnitedHealth Group Inc UNH | $276.2B | 0.3 | 22.9 | $113.7B | 2.7% | 1181.0% | Compare → |
📊 Explore More Stock Analysis
Get comprehensive Deep Value Reports for thousands of stocks. Research risk, financial health, and investment potential with our AI-powered analysis.
How Prime Medicine Inc Makes Money
Prime Medicine is a biotechnology company focused on developing a new class of precision gene editing medicines based on its proprietary 'Prime Editing' technology. This technology aims to directly correct disease-causing mutations at their source within the genome. The company's business model involves extensive research and development to discover, develop, and eventually commercialize novel therapeutic candidates for genetic diseases. Revenue is currently generated primarily through strategic collaborations and potentially grants, with future revenue expected from licensing agreements and, ultimately, from the sales of approved therapies.
Read Full Business Model BreakdownFAQ
What is the DVR Score for Prime Medicine Inc (PRME)?
As of May 1, 2026, Prime Medicine Inc has a DVR Score of 3.8 out of 10, placing it in the "Risk Trap" category. This score is generated by our AI-powered deep value analysis framework that evaluates growth potential, financial health, competitive moat, and risk factors.
What is the market capitalization of Prime Medicine Inc?
Prime Medicine Inc's market capitalization is approximately $640.1M. The company operates in the Healthcare sector within the Biotechnology industry.
What ticker symbol does Prime Medicine Inc use?
PRME is the ticker symbol for Prime Medicine Inc. The company trades on the NGM.
What is the risk level for PRME stock?
Our analysis rates Prime Medicine Inc's overall risk as Aggressive. This assessment considers execution risk, market risk, financial risk, competitive risk, and regulatory risk. For a full breakdown, see the risk analysis section above.
What is the P/E ratio of PRME?
Prime Medicine Inc currently has a price-to-earnings (P/E) ratio of -6.5. This is below the market average, which could indicate the stock is undervalued or facing headwinds.
Is Prime Medicine Inc's revenue growing?
Prime Medicine Inc has reported revenue growth of 55.3%. The company is showing strong top-line momentum.
Is PRME stock profitable?
Prime Medicine Inc has a profit margin of -4342.4%. The company is currently unprofitable.
How often is the PRME DVR analysis updated?
Our AI-powered analysis of Prime Medicine Inc is refreshed regularly to incorporate the latest financial data, market conditions, and news. The most recent update was on May 1, 2026.
Important Disclaimer – Not Financial Advice
Deep Value Reports is an independent research platform for educational and informational purposes only. We are not financial advisors, investment advisors, or licensed professionals. The analysis, scores, and information provided on this page for PRME (Prime Medicine Inc) should not be construed as personalized investment advice, a recommendation to buy or sell any security, or an offer to provide investment advisory services.
All investments involve risk, including the potential loss of principal. Past performance does not guarantee future results. Always conduct your own research, consider your financial situation, and consult with a qualified financial advisor before making any investment decisions.